In the phase III OPTIMA trial, patients with high-risk anatomical features like node positivity and large tumors did not benefit from adding chemotherapy to endocrine therapy if their genomic score was low. Invasive breast cancer-free survival was identical between chemo and endocrine-only arms for patients with scores under 60.
DESTINY-Breast05 demonstrated a 53% improvement in invasive disease-free survival over T-DM1, but exhibited a 9.6% interstitial lung disease rate, including two fatal cases. Dr. Abraham noted concurrent radiation does not elevate this risk, making early symptom recognition and rapid steroid intervention critical.
Patients receiving sacituzumab govitecan frequently face neutropenia and diarrhea, especially when heavily pretreated. Dr. Abraham recommends initiating treatment at the full 10 mg/kg dose on days one and eight, followed by dose reductions to 7.5 mg/kg or day-eight Neulastra administration to allow one recovery week.
Dr. Abraham stresses that physicians, nurses, APPs, and pharmacists must actively engage in developing artificial intelligence rather than letting outside technologists dictate healthcare tools. Without clinical voices steering adoption, external developers could implement systems without understanding patient-centered safety, trust, and practical clinical care.
While academic specialists focus entirely on single diseases, community oncologists treat approximately 70% of cancer patients across constantly shifting malignancies. AI search and summary tools help general oncologists rapidly digest complex literature and filter the explosion of trial data between seeing patients with diverse diagnoses.
